Last Updated:
Create account to add to watchlist!
Create account to add to watchlist!

Spindletop Health Acquisition Corp. - SHCA

  • Commons



    SHCA Vol: 0.0

  • Warrants



    SHCAW Vol: 0.0

  • Units



    SHCAU Vol: 0.0

Average: 0
Rating Count: 0
You Rated: Not rated

Please log in to rate.

SPAC Stats

Market Cap: 0.0
Average Volume: 0.0
52W Range: $0.00 - $0.00
Weekly %: +0.00%
Monthly %: +0.00%
Inst Owners: 0


Target: Searching
Days Since IPO: 595
Unit composition:
Each unit has an offering price of $10.00 and consists of one share of our Class A common stock and one-third of one redeemable warrant
Trust Size: 20000000.0M

🕵Stocktwit Mentions

Quantisnow posted at 2023-02-09T15:10:34Z

$SHCA 📜 SEC Form SC 13G/A filed by Spindletop Health Acquisition Corp. (Amendment) 45 seconds delayed.

Quantisnow posted at 2023-01-25T15:43:06Z

$SHCA 📜 SEC Form SC 13G/A filed by Spindletop Health Acquisition Corp. (Amendment) Get the next market-moving insight 45 seconds early at ➡️ ⬅️

ken5 posted at 2023-01-11T15:23:49Z

$SHCa many people got cancer because this dirty corp. money can not buy life back

shortablestocks posted at 2022-12-30T16:10:57Z

Zero shares available to short currently in $SHCA.

shortablestocks posted at 2022-12-29T16:11:11Z

Zero shares available to short currently in $SHCA.


Our officers and directors are as follows: Name Age Position Evan S. Melrose, M.D., MBA 51 Chief Executive Officer, Chief Financial Officer and Director James H. Henry, CPA 63 Chairman of the Board of Directors Steve Whitlock, MBA 59 Secretary JD Moore, MBA 48 Senior Vice President, Corporate Development Kelly Huang, Ph.D. 52 Chief Operating Officer Craig Cordola, MBA 49 Director Todd Fruchterman, M.D., Ph.D. 51 Director David Nash, M.D., MBA 65 Director Evan S. Melrose, M.D., MBA Dr. Melrose serves as our Chief Executive Officer, Chief Financial Officer and on our board of directors. With 25 years of experience in the healthcare industry, Dr. Melrose has significant expertise across public and private healthcare investing. As the Founding Managing Director of Spindletop, Dr. Melrose provides pivotal expansion capital for healthcare investments. Prior to Spindletop, he was Founding Managing Director of PTV Sciences, an Austin-based venture capital firm, and a Director with Burrill & Company, a San Francisco-based life science private equity/venture capital firm. Dr. Melrose has extensive operating, capital markets and mergers and acquisitions experience, including selling companies to SPACs and many initial public offerings. His extensive current and prior board memberships include Bioventus (NASDAQ: BVS), Castle Biosciences, Inc. (NASDAQ: CSTL), Intersect ENT (NASDAQ: XENT), Asuragen, BioSET (acquired by Ferring Pharmaceuticals), BioForm Medical (NASDAQ: BFRM), BioMimetic Therapeutics (NASDAQ: BMTI) and Inhibitex (NASDAQ: INHX). Dr. Melrose’s broad experience as a physician includes: clinical practice, faculty appointments at the University of California- San Francisco, University of Pennsylvania and Baylor College of Medicine, outcomes and biomedical research, and work in health policy on Capitol Hill. He has served in leadership roles in organized medicine and has received multiple leadership awards including the AMA/Glaxo Achievement Award. Dr. Melrose received his BA from the University of Pennsylvania, his M.D. from Indiana University School of Medicine and an MBA from The Wharton School of Business. He is a member of YPO International, a Board Leadership Fellow of the National Association of Corporate Directors, and serves on the boards of HNI Healthcare, Sanova Dermatology, Spindletop Pain Holdings. Dr. Melrose served as a prestigious Health Innovator Fellow for the Aspen Institute and was admitted into the Aspen Global Leadership Network. Independent Directors James H. Henry, CPA Mr. Henry serves as our Chairman of the Board. James brings over 37 years of financial accounting experience from PricewaterhouseCoopers LLC (PwC), where he held numerous leadership and senior client roles, including Global Healthcare Leader, Vice Chair—Industries & Sectors, and Managing Partner for the San Francisco area. As Healthcare Leader, Mr. Henry led the growth of PwC’s Health Industries business to become a leading global consultancy and formed the Health Research Institute. He currently serves on the Board of Directors of Spindletop Pain Management Holdings and Unison Energy. Previously, Mr. Henry served as an advisor to the Bay Area Council Economic Institute and UCSF’s Global Health Group. Mr. Henry earned a B.S. in Business Administration (Accounting) from San Diego State University. He is a Certified Public Accountant (CPA) in Texas and California and a member of the National Association of 123 Table of Contents Corporate Directors. Mr. Henry’s qualifications to serve on our board of directors include his healthcare and life sciences experience, his extensive knowledge of financial accounting, internal controls and public company reporting and his experience serving on the board of directors of other companies. Craig Cordola, MBA Mr. Cordola brings significant operating expertise within healthcare systems as Executive Vice President and Chief Operating Officer for Ascension, one of the largest Catholic healthcare organizations in the country with more than 150,000 associates and 40,000 affiliated providers. Mr. Cordola has overall responsibility for the healthcare and business operations in support of the Ascension Mission, as well as responsibility for Ascension subsidiaries including Medxcel Facilities Management and The Resource Group, Ascension’s group purchasing organization. Mr. Cordola joined Ascension in September 2017 as the President and Chief Executive Officer / Ministry Market Executive for Ascension Texas. He previously served as Senior Vice President of the Memorial Hermann Health System in southeast Texas as President of its Central/West Region. In this role, he also had Executive responsibility for their Academic relationship with The University of Texas Health Science Center—Houston. Mr. Cordola graduated with honors from The University of Texas at Austin with a degree in Psychology and continued his studies at the University of Houston-Clear Lake, where he earned dual degrees with a Master of Healthcare Administration and a Master of Business Administration. Mr. Cordola’s qualifications to serve on our board of directors include his extensive healthcare system operations experience. Todd Fruchterman, M.D., Ph.D. Dr. Fruchterman brings his qualifications and experience as an M.D., Ph.D. and proven business executive in public medical device companies, with a demonstrated track record of scaling disruptive technologies. Dr. Fruchterman was recently appointed CEO of Butterfly Network (NASDAQ: BFLY), a successful de-SPAC merger of Longview Acquisition Corp. and Butterfly Network. Previously, he was President of the Reliability Solutions segment of Flex (NASDAQ: FLEX) where he oversaw the Health Solutions, Automotive and Industrial business units. Prior to Flex, he served ten years at 3M Company (NYSE: MMM) where he held multiple roles, most recently as President and General Manager of the Medical Solutions Division. In his 23-year career, Dr. Fruchterman also held leadership positions at Kinetic Concepts, Inc., where he was Executive Vice President, Chief Technology Officer, and Chief Medical Officer; at Johnson & Johnson, where he held various key positions including directing worldwide biosurgical R&D for the Ethicon division; and at Response Genetics, Inc., where he was President, Chief Executive Officer, and Chief Operating Officer. Dr. Fruchterman has served on the board of AdvaMed, and in 2019 was a core participant in the U.S. Department of HHS Innovation and Investment Summit. He has served on the Leonard Davis Institute of Health Economics Executive Advisory Board, BioMed SA Board, LifeScience Alley Board and the Board of the Texas Life Science Center. Dr. Fruchterman received his B.A. and M.D. from the University of Pennsylvania and his Ph.D. from the University of Louisville. Dr. Fruchterman’s qualifications to serve on our board of directors include his extensive leadership, commercial, operational and technical experience in public healthcare companies. David Nash, M.D., MBA Dr. Nash brings a career as a distinguished physician, academic scholar and public health expert. Dr. Nash is the Founding Dean Emeritus of the nation’s first college of population health on the campus of Jefferson University in Philadelphia PA. He remains on an endowed chair in health policy, as the special assistant to the CEO of Jefferson Health, and a board member of the ACO affiliated with the health system. Dr. Nash had a 30-year career at Jefferson, and as a distinguished professor, helped usher in the era of public accountability for the outcomes of medical care, and more recently, the ascendancy of value-based payment and population health management. Dr. Nash previously served as a board member for Humana (NYSE: HUM) for nearly a decade and at Mercy Health. He is currently a board member with The Geisinger Commonwealth School of Medicine and 124 Table of Contents ANI Pharmaceuticals (NASDAQ: ANIP), a public company committed to affordable generic drugs. He has consulted for numerous companies in health information technology, biotech, continuing medical education, remote patient monitoring and other disruptive health-related technologies. Dr. Nash received his M.D. from the University of Rochester and his MBA from the Wharton School of Business. Dr. Nash’s qualifications to serve on our board of directors include a distinguished academic career, expertise in public health policy and his previous and current public board memberships. Executive Officers Kelly Huang, Ph.D. Dr. Huang serves as our Chief Operating Officer. Dr. Huang brings over 25 years of experience leading global businesses in life sciences and consumer healthcare. He currently serves as a Managing Director with Spindletop. His prior roles include Head of the Nutri-Therapeutic Division of L-Nutra, Inc., a leading nutri-tech company, President, CEO, and Board Director for Obalon Therapeutics (NASDAQ: OBLN), and General Manager of Nestle Skin Health’s Galderma LP aesthetics business, providing commercial leadership for iconic brands including Restylane, Dysport and Sculptra. Previously, Dr. Huang also served as President of the Urology Device and Services business at HealthTronics Dr. Huang spent 16 years with Johnson & Johnson (NYSE: JNJ), including as Vice President of Research & Development and corporate officer of Neutrogena Corporation and as Vice President with Johnson & Johnson Development Corporation. Dr. Huang earned a B.S. in Chemical Engineering from the University of Massachusetts at Amherst, followed by an M.S. and Ph.D. in Chemical Engineering from Stanford University. He was a member of the board of Sensei, LLC, a mobile health company and HITS, a private equity-owned health information technology company. He is a Board Leadership Fellow of the National Association of Corporate Directors and currently serves on the boards of Sanova Dermatology, the Princeton Innovation Accelerator (USA Hub of Commonwealth Center for Digital Health) and on the editorial board of American Drug and Health Benefits. JD Moore, MBA Mr. Moore serves as our Senior Vice President, Corporate Development. Mr. Moore brings deep experience in growing global businesses and platforms, having completed over $50 billion in transactions in his career. He has been responsible for global strategy and business development functions for several medical device companies whose activities included strategic partnerships, minority investments, joint ventures and acquisitions. Most recently, he was head of Business Development for Tricity Pain Associates, a leading provider of interventional pain management services. Previously, Mr. Moore served as Head of Business Development and Strategy for Johnson & Johnson (NYSE: JNJ), Head of Strategy and Business Development for Medtronic Diabetes (NYSE: MDT) and Head of Mergers and Acquisitions for CareFusion Corp. Prior to his corporate executive experience, he was an investment banker in New York focused on mergers and acquisitions in the healthcare services and medical device sectors with JP Morgan. Mr. Moore received an MBA from Michigan Ross School of Business and a BBA from the University of Texas at Austin. He is a member of the University of Texas Development Board and the McCombs School of Business Healthcare Innovation Advisory Council. Steve Whitlock, MBA Mr. Whitlock serves as our Secretary. Mr. Whitlock has over 25 years of experience in the orthopedic industry, as well as an investor, having co-founded Path4 Ventures and served as an Operating Venture Partner with PTV Sciences. He currently serves as a Managing Director with Spindletop. During his tenure working in the venture space, he co-founded LDR Spine USA, where he served as President and CEO at its inception 125 Table of Contents (NASDAQ: LDRH, was acquired by Zimmer Biomet in 2016 for $1 billion following its 2013 IPO), and Spinal Restoration. Mr. Whitlock served on the boards of LDR Holdings, Spinal Restoration, and Ortho Kinematics. Steve began his career with Centerpulse Orthopedics (formerly Intermedics and Sulzer Orthopedics) where he held various executive management roles in Global Research and Development, New Business Development, and Global Products in the areas of total joints, sports medicine, trauma, and orthobiologics. He was also a member of the executive team responsible for the company turnaround following the largest product recall in orthopedic devices, leading to an acquisition by Zimmer in 2003 for $3.2 billion. Mr. Whitlock holds a B.S. in Mechanical Engineering degree from Texas A&M University and an MBA from Embry—Riddle Aeronautical University. Bob McDonald, M.D., MBA Dr. McDonald serves as our Senior Advisor. Dr. McDonald has 30 years of experience as a physician leader in reimbursement consulting with healthcare insurance and pharma expertise. Currently, he is the President and Founder of Aledo Consulting, Inc. He also currently serves as an Operating Venture Partner with Spindletop. Prior to this role, he served in a variety of senior medical and operations positions at Anthem Blue Cross and Blue Shield (NYSE: ANTM) and its predecessor company, The Associated Group, including Medical Director of Medical Policy, Medical Director of Anthem Prescription Management, LLC and Medical Director of Health Care Management, Anthem Inc. Prior to Anthem, he served for three years at Eli Lilly and Company (NYSE: LLY) as a Health Economics Research Physician performing cost effectiveness analyses both as part of developmental trials and on site at health plans across the United States. Dr. McDonald received his M.D. from the University of Texas Southwestern Medical School and his MBA from The Wharton School of Business. Number and Terms of Office of Officers and Directors We currently have five directors, with each director holding office for a two-year term. Prior to the completion of an initial business combination, any vacancy on the board of directors may be filled by a nominee chosen by holders of a majority of our board of directors. Additionally, in accordance with Nasdaq corporate governance requirements, we are not required to hold an annual meeting until one full year after our first fiscal year end following our listing on Nasdaq. As a result, we may not hold an annual meeting of stockholders until after we consummate our initial business combination. Pursuant to an agreement to be entered into concurrently with the issuance and sale of the securities in this offering, our sponsor, upon consummation of an initial business combination, will be entitled to nominate two individuals for election to our board of directors. Our officers are appointed by the board of directors and serve at the discretion of the board of directors. Our board of directors is authorized to appoint persons to the offices set forth in our bylaws as it deems appropriate. Our bylaws will provide that our officers may consist of a Chairman of the Board, Chief Executive Officer, Chief Financial Officer, President, Vice Presidents, Secretary, Treasurer, Assistant Secretaries and such other offices as may be determined by the board of directors. Director Independence An “independent director” is defined generally as a person other than an officer or employee of the company or its subsidiaries or any other individual having a relationship, which, in the opinion of the company’s board of directors, would interfere with the director’s exercise of independent judgment in carrying out the responsibilities of a director. Upon the effectiveness of the registration statement of which this prospectus forms a part, we expect to have three “independent directors” as defined in the Nasdaq listing rules and applicable SEC rules prior 126 Table of Contents to completion of this offering. We expect a majority of our board of directors to be comprised of independent directors within 12 months from the date of listing to comply with the majority independent board requirement in Rule 5605(b) of the Nasdaq listing rules. Our board has determined that each of Craig Cordola, Todd Fruchterman and David Nash are independent directors under applicable SEC and Nasdaq listing rules. Our independent directors will have regularly scheduled meetings at which only independent directors are present. Officer and Director Compensation In no event will our sponsor or any of our existing officers or directors, or any entity with which our sponsor or officers are affiliated, be paid any finder’s fee, reimbursement, consulting fee, monies in respect of any payment of a loan or other compensation by the Company prior to, or in connection with any services rendered for any services they render in order to effectuate, the completion of our initial business combination (regardless of the type of transaction that it is). However, these individuals will be reimbursed for any out-of-pocket expenses incurred in connection with activities on our behalf such as identifying potential target businesses and performing due diligence on suitable business combinations. We do not have a policy that prohibits our sponsor, officers or directors, or any of their respective affiliates, from negotiating for the reimbursement of out-of-pocket expenses by a target business. Our audit committee will review on a quarterly basis all payments that were made to our sponsor, officers or directors, or our or their affiliates. Any such payments prior to an initial business combination will be made using funds held outside the trust account. Other than quarterly audit committee review of such payments, we do not expect to have any additional controls in place governing our reimbursement payments to our directors and officers for their out-of-pocket expenses incurred in connection with identifying and consummating an initial business combination. On March 12, 2021, we entered into a Strategic Services Agreement and Confidential Information and Invention Assignment Agreement with Messrs. Huang, Whitlock and Moore, our Chief Operating Officer, Secretary and Senior Vice President, Corporate Development, respectively. Messrs. Huang, Whitlock and Moore previously purchased 50,000 shares of Class B Common Stock of the Company from sponsor and shall not receive any additional compensation from the Company during the term of their respective Services Agreement other than the shares of Class B Common Stock previously purchased from sponsor (which are subject to vesting terms as set forth in the definitive documentation with respect thereto). After the completion of our initial business combination, directors or members of our management team who remain with us may be paid consulting or management fees from the combined company. These fees will be disclosed to stockholders in accordance with applicable rules and regulations, to the extent then known, in the tender offer materials or proxy solicitation materials furnished to our stockholders in connection with a proposed initial business combination. We have not established any limit on the amount of such fees that may be paid by the combined company to our directors or members of management. It is unlikely the amount of such compensation will be known at the time of the proposed initial business combination, because the directors of the post-combination business will be responsible for determining officer and director compensation. Any compensation to be paid to our officers will be determined, or recommended to the board of directors for determination, either by a compensation committee constituted solely by independent directors or by a majority of the independent directors on our board of directors. Prior to the completion of our initial business combination, any compensation paid to our Chief Executive Officer or other executive officers

SEC Filings

Form Type Form Description Filing Date Document Link
10-Q FORM 10-Q 2022-08-15
10-Q FORM 10-Q 2022-05-23
NT 10-Q NT 10-Q 2022-05-16
10-K FORM 10-K 2022-04-14
NT 10-K NT 10-K 2022-04-01
SC 13G SCHEDULE 13G 2022-02-17
SC 13G/A FORM SC 13G/A 2022-02-14
SC 13G/A SC 13G/A 2022-02-14
SC 13G SC 13G 2022-02-08
8-K 8-K 2021-12-21
10-Q FORM 10-Q 2021-12-20
8-K FORM 8-K 2021-11-15
SC 13G FORM SC 13G 2021-11-12
4 FORM 4 SUBMISSION 2021-11-12
4 FORM 4 SUBMISSION 2021-11-12
SC 13G SC 13G 2021-11-12
8-K FORM 8-K 2021-11-08
424B4 FORM 424(B)(4) 2021-11-05
EFFECT 2021-11-03
3 FORM 3 SUBMISSION 2021-11-03
3 FORM 3 SUBMISSION 2021-11-03
3 FORM 3 SUBMISSION 2021-11-03
3 FORM 3 SUBMISSION 2021-11-03
3 FORM 3 SUBMISSION 2021-11-03
3 FORM 3 SUBMISSION 2021-11-03
3 FORM 3 SUBMISSION 2021-11-03
3 FORM 3 SUBMISSION 2021-11-03
3 FORM 3 SUBMISSION 2021-11-03
CERT 2021-11-03
8-A12B FORM 8-A12B 2021-11-03
CORRESP 2021-11-01
CORRESP 2021-11-01
S-1/A FORM S-1/A 2021-10-18
CORRESP 2021-08-19
S-1/A FORM S-1/A 2021-08-19
UPLOAD 2021-04-15
S-1 FORM S-1 2021-03-19